Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Renal disease company Tricida Inc. (South San Francisco, Calif.) filed to raise up to $150 million in an IPO on NASDAQ underwritten by
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury